Listen to this article

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations.

In a filing with the state Department of Labor & Workforce Development, the company said layoffs will begin April 30 and conclude May 31 of this year.

A spokesperson for Organon did not immediately respond to a request for comment.

Formed in 2021 through a spinoff from Merck, Organon’s offerings include medicines and products in therapeutic areas such as women’s health and biosimilars.

In recent months, the company’s portfolio has experienced several changes, including the$1.2 billion acquisition in September 2024 of Dermavant. Organon also lost exclusivity in Europe and Japan for its second-largest product, cholesterol-lowering drug Atozet.

Since launching a restructuring campaign last year, Organon has already let go about 5% of its workforce, according to a February filing with the U.S. Securities and Exchange Commission. The company also said it expects to continue adjusting headcount and functions this year and expects another 5% head count reduction.

Streamlining operations

As of Dec. 31, 2024, Organon had over 10,000 employees worldwide. About 1,800 of those workers are in the U.S., the filing said.

During the company’s fourth quarter earnings call in February, CEO Kevin Ali emphasized a “lean culture focused on profitable growth.”

Matt Walsh, Organon’s chief financial officer, described the changes over the past two years as “belt tightening.” He went on to say, “This round of restructuring … is more significant. We did look at our organization more holistically and really did some pretty significant streamlining of our spans and layers and the way that our various functions work together.”

Similar to Organon, Reckitt Benckiser Group is also undergoing a revamp. The multinational company plans to eliminate 190 jobs at its U.S. headquarters in Parsippany by Aug. 1.

The reductions are part of that company’s plan to shift to a new operating model starting in 2025. Under the changes announced in July 2024, Reckitt aims to reshape itself to a “simpler, more effective organization with fewer management layers and reduced duplication.” Additionally, it aims to focus on “high-growth, high-margin Powerbrands.”